Congrats to @sensible_bio (YC S21) on their $47M Series A! They engineer living cells to manufacture mRNA, turning the cell itself into the factory. Today's mRNA is made in cell-free processes that work fine for vaccines, where doses are small. The next generation of mRNA medicines, like in vivo CAR-T and gene editing, needs far higher doses and far purer mRNA than those methods can deliver. Sensible is closing that gap with a platform that can already produce around 1,000 mRNA sequences per…